Intravenous Autologous Bone Marrow-derived Stem Cells Therapy for Patients With Acute Ischemic Stroke

This study has been completed.
Sponsor:
Collaborator:
Department of Biotechnology-DBT India
Information provided by (Responsible Party):
Manipal Acunova Ltd.
ClinicalTrials.gov Identifier:
NCT01501773
First received: December 26, 2011
Last updated: NA
Last verified: December 2011
History: No changes posted

December 26, 2011
December 26, 2011
October 2008
October 2011   (final data collection date for primary outcome measure)
Barthel index score [ Time Frame: six month post randomization ] [ Designated as safety issue: Yes ]
The primary efficacy outcome is difference between the two groups in the modified Barthel index score at six month post randomization.
Same as current
No Changes Posted
NIHSS score and functional status [ Time Frame: 3, 6 and 12 months post randomization ] [ Designated as safety issue: Yes ]
  1. NIHSS score at 6 months and one year post randomization.
  2. And degree of handicap as measured by Modified Ranking scale administered at 3, 6 and 12 months post randomization and functional status at 6 months and 12 months post randomization
Same as current
Not Provided
Not Provided
 
Intravenous Autologous Bone Marrow-derived Stem Cells Therapy for Patients With Acute Ischemic Stroke
Phase II Intravenous Autologous Bone Marrow-derived Stem Cells Therapy for Patients With Acute Ischemic Stroke

A multi-centric initiative to study safety,feasibility and efficacy of using intravenous autologous bone marrow mononuclear cells(BMMC) in patients with acute ischemic stroke.This phase of study is visualised as phase 2 study and will aim to determine dose response gradient of stem cell therapy and to explore if there is favorable risk to benefit ratio for autologous stem cell therapy in patient with acute ischamic stroke.

This phase of the study will have two arms developed through random allocation: one arm for intravenous autologous bone marrow derived stem cell/mononuclear cells(BMMC arm); and second control arm. Patients with acute ischaemic stroke between 7-30 days after onset with moderae severity in sable condition will be entered into the study after informed consent. Both arms will receive standard treatment but BMMC arm will,in addition,have bone marrow aspiration and receive autologous 30-500 million bone marrow mononuclear cells intravenously on the day of randomisation and all patients will be followed at DaY 7 ± days, Day 90(-7 days to +14 days), Day 180(-7 days to +28 days)and Day 365 (-7 days to + 28 days). A number of safety and efficacy variables will be measured. This phase 2 study will aim to determine dose response gradient of stem cell therapy and to explore if results have a favourable risk to benefit ratio to justify a phase 3 study. This will be the first human trial to determine and compare favourable and unfavourable effects of bone marrow mononuclear cells(mainly CD34) in acute ischamic stroke and also the first multi-centric study with potential to achieve a reasonable sample size in a relatively short time.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Acute Stroke
Biological: Autologous bone marrow stem cell
Autologous bone marrow stem cell have bone marrow aspiration and receive 30-500 million bone marrow mononuclear cells intravenously on the day of randomization.
  • Experimental: Autologous bone marrow stem cell
    Intervention: Biological: Autologous bone marrow stem cell
  • No Intervention: Control
Prasad K, Mohanty S, Bhatia R, Srivastava MV, Garg A, Srivastava A, Goyal V, Tripathi M, Kumar A, Bal C, Vij A, Mishra NK. Autologous intravenous bone marrow mononuclear cell therapy for patients with subacute ischaemic stroke: a pilot study. Indian J Med Res. 2012 Aug;136(2):221-8.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
120
October 2011
October 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Sudden onset of focal neurologic deficit or impairment of consciousness.
  2. CT or MRI scan of head showing no haematoma and relevant lesions within the MCA and ACA territory.
  3. Age between 30 -70 years (after amendment 18 -70 years).
  4. >7 to </=30 days passed since the onset of the qualifying event.
  5. Glasgow Coma Scale score of >8 at the time of randomization, in aphasic Eye and Motor score of >6.
  6. Modified Barthel Index score of 50 or less at the time of randomization.
  7. NHISS score of 7 or more points and inability to walk unaided or raise upper limb by 90 degree.
  8. Patient is stable. ( normal respiration, afebrile, BP less than mean arterial pressure of 125 mm of Hg, fasting blood sugar < 200 mg% and normal urea/electrolytes for at least 48 hours.)

Exclusion Criteria: -

  1. Lacunar syndrome
  2. Intubation
  3. Posterior circulation stroke
  4. Co morbidity likely to limit survival to less than 3 years eg. Hepatic or renal failure.
  5. Inaccessibility for follow up.
  6. Allergy to local anaesthetic.
  7. Unwillingness to provide written informed consent.
  8. Symptom of acute myocardial infarction or acute involvement of any other organ.
  9. Pregnancy 10. HIV positive 11. Patient is a part of any other trial in last 6 months.
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
India
 
NCT01501773
INVEST
Yes
Manipal Acunova Ltd.
Manipal Acunova Ltd.
Department of Biotechnology-DBT India
Principal Investigator: Dr. Kameshwar Prasad, MBBS, MD All India Institute of Medical Sciences, New Delhi
Principal Investigator: Dr. Usha Kant Misra, MBBS, MD, DM Sanjay Gandhi Postgraduate Institute of Medical Sciences
Principal Investigator: Dr. R.S Sarkar Armed Forces Medical College
Principal Investigator: Dr. Sudesh Kumar Prabhakar, MBBS, MD, DM Post Graduate Institute of Medical Education and Research
Principal Investigator: Dr. Sharat Joshi, MBBS,MD, DM Army R & R Hospital
Manipal Acunova Ltd.
December 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP